Form 4 for NAMS NewAmsterdam Pharma Co N.V.
Accepted 2026-06-24 16:10:03 ET · period of report 2026-06-22 · accession 0001193125-26-281062 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-06-24 16:10 | 2026-06-22 | NAMS | Kooij Louise Frederika | CAO | M - OptEx | $11.28 | +40.0K | 64.4K | +164% | +$451.0K |
| DMT | 2026-06-24 16:10 | 2026-06-22 | NAMS | Kooij Louise Frederika | CAO | S - Sale+OE | $30.20 | -40.0K | 24.4K | -62% | -$1.21M |
| DMT | 2026-06-24 16:10 | 2026-06-22 | NAMS | Kooij Louise Frederika | CAO | M - OptEx | $0.00 | -40.0K | 35.0K | -53% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2026-06-22 | M | A | 25,000 | $10.90 | 49,353 | D | — | — | |
| 2 | Common | Ordinary Shares | 2026-06-22 | M | A | 15,000 | $11.90 | 64,353 | D | — | — | |
| 3 | Common | Ordinary Shares | 2026-06-22 | S | D | 39,700 | $30.20 | 24,653 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.73 to $30.72 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. (F2) Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting. |
| 4 | Common | Ordinary Shares | 2026-06-22 | S | D | 300 | $30.73 | 24,353 | D | — | — | (F2) Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting. |
| 5 | Derivative | Option (right to buy) | 2026-06-22 | M | D | 25,000 | $0.00 | 43,134 | D | $10.90 · — to 2033-01-01 | 25,000 Ordinary Shares | (F3) The option was granted on January 1, 2023. 25% of the shares underlying the option vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. |
| 6 | Derivative | Option (right to buy) | 2026-06-22 | M | D | 15,000 | $0.00 | 35,000 | D | $11.90 · — to 2033-05-18 | 15,000 Ordinary Shares | (F4) The option was granted on May 18, 2023. 25% of the shares underlying the option vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. |